A5018041476- Angiogenesis and VEGF in Cancer
- Cancer, Hypoxia, and Metabolism
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Nitric Oxide and Endothelin Effects
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Cancer Research and Treatments
- RNA Interference and Gene Delivery
- Cancer, Lipids, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Advanced NMR Techniques and Applications
- Virus-based gene therapy research
- Electron Spin Resonance Studies
- Advanced Fluorescence Microscopy Techniques
- Cell Adhesion Molecules Research
- Sarcoma Diagnosis and Treatment
- Click Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Optical Coherence Tomography Applications
- Hemoglobin structure and function
- Synthesis and biological activity
- Photoacoustic and Ultrasonic Imaging
- Immune cells in cancer
University of Sheffield
2011-2021
Yorkshire Cancer Research
2012-2014
Cancer Research UK
1999-2010
Mount Vernon Hospital
1999-2010
Northwood University
2008
Royal Hallamshire Hospital
2004-2007
The Honourable Society of Lincoln's Inn
2005
Howard Hughes Medical Institute
2005
Duke University Hospital
2005
Duke Medical Center
2005
Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and discover improved methods prevent, diagnose treat cancer. Excellent standards of animal care are fully consistent with conduct high quality cancer research. Here we provide updated guidelines on welfare use animals in All should incorporate 3Rs: replacement, reduction refinement. Focusing welfare, present recommendations all aspects research, including: study design, statistics pilot...
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports outcome a workshop that considered methodology design studies, recommending how this new tool might best be used.
Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt blood vessels in tumors and induce tumor necrosis. However, rapidly repopulate after treatment with compounds. Here, we show that CA4P-induced vessel narrowing, hypoxia, hemorrhagic necrosis murine mammary were accompanied by elevated levels of the chemokine CXCL12 infiltration proangiogenic TIE2-expressing macrophages (TEMs). Inhibiting TEM recruitment to CA4P-treated either interfering...
Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related blood flow and permeability tumor normal tissue after CA4P treatment.Changes kinetic DCE-MRI (transfer constant [Ktrans] area under medium-time curve [AUC]) over 24 hours treatment with measured 18 patients phase I trial compared those obtained the rat P22 carcinosarcoma model, using same...
Abstract Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to these poorly understood. We evaluated consequences of modifying vascular morphology and function on therapeutic response combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. Mouse fibrosarcoma cell lines capable expressing all endothelial growth factor (VEGF) isoforms (control) or only single VEGF (VEGF120,...
This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G 6 ) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation SVEC4-10 murine endothelial cells and neovascularization in chick embryo chorioallantoic membrane (CAM) assay. Intravenous administration PLL-dendrimer into C57BL/6 mice inhibited vascularisation Matrigel plugs implanted...
The anti-vascular effects of the tubulin binding agent, disodium combretastatin A-4 3-O-phosphate (CA-4-P), have been investigated in rat P22 carcinosarcoma by measurements radiolabelled iodoantipyrine uptake and dynamic contrast-enhanced MRI. estimates absolute tumour blood flow showed a reduction from 0.35 to 0.04 ml g(-1) min(-1) 6 h after 10 mg kg(-1) CA-4-P <0.01 100 kg(-1). Tumour recovered control values 24 CA-4-P, but there was no recovery higher dose. Dynamic MR images were obtained...